Viagra, a medication manufactured by Pfizer, has achieved significant sales figures since its approval. The drug is prescribed to treat erectile dysfunction.
How much revenue has Viagra generated?
Viagra has been a substantial revenue generator for Pfizer. Reports indicate that by 2012, Viagra had generated over $2 billion in sales for Pfizer [1]. More recent figures show that in 2023, Pfizer's erectile dysfunction portfolio, which includes Viagra, achieved sales of $2.04 billion [2].
When does Viagra's patent expire?
Pfizer's primary U.S. patent for Viagra expired in 2013 [3]. This patent protected the composition of matter for sildenafil citrate, the active ingredient in Viagra. Following patent expiry, generic versions of sildenafil became available.
What are the sales trends for Viagra?
After the expiration of Viagra's primary patent and the subsequent introduction of generic sildenafil, sales of the branded Viagra product have declined from their peak. However, the overall market for sildenafil citrate, including both branded and generic versions, continues to be substantial. Pfizer's 2023 financial reports indicate continued strong performance from its erectile dysfunction product line [2].
What are the key statistics for erectile dysfunction drug sales?
The erectile dysfunction market is significant. In 2023, Pfizer reported $2.04 billion in sales for its erectile dysfunction treatments, which primarily consist of Viagra and its successor, the U.S. Food and Drug Administration (FDA)-approved sildenafil [2]. These figures highlight the sustained demand for effective treatments for erectile dysfunction. DrugPatentWatch.com tracks patents and market exclusivity for pharmaceutical products, providing data that influences these sales trends [4].